Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | CA9 | Q16790 | 5/20 | 0.68 |
| ▸ | CA12 | O43570 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | CA1 | P00915 | 6/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | MMP2 | P08253 | 4/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 3/20 | 0.53 |
| ▸ | MMP9 | P14780 | 3/20 | 0.53 |
| ▸ | MMP13 | P45452 | 3/20 | 0.53 |
| ▸ | MMP8 | P22894 | 2/20 | 0.53 |
| ▸ | MMP3 | P08254 | 2/20 | 0.53 |
| ▸ | MMP7 | P09237 | 2/20 | 0.53 |
| ▸ | CA4 | P22748 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | GBA1 | P04062 | 1/20 | 0.51 |
| ▸ | MMP14 | P50281 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16519484 | 1.00 | CA2 (0.68) | CA2ALDH1A1CA9CA12TSHR | |
| SCHEMBL16519485 | 1.00 | CA2 (0.68) | CA2ALDH1A1CA9CA12TSHR | |
| SCHEMBL6324018 | 0.86 | ADAMTS4 (0.53) | CA2ALDH1A1CA9CA12TSHR | |
| SCHEMBL6324016 | 0.86 | ADAMTS4 (0.53) | CA2ALDH1A1CA9CA12TSHR | |
| SCHEMBL6321461 | 0.84 | MMP2 (0.56) | CA2ALDH1A1CA9CA12TSHR | |
| SCHEMBL15801255 | 0.84 | NR3C1 (0.51) | CA2ALDH1A1CA9CA12TSHR | |
| SCHEMBL14316552 | 0.84 | NR3C1 (0.51) | CA2ALDH1A1CA9CA12TSHR | |
| SCHEMBL13014153 | 0.84 | ALDH1A1 (0.49) | CA2ALDH1A1CA9CA12TSHR | |
| SCHEMBL13014370 | 0.84 | ALDH1A1 (0.49) | CA2ALDH1A1CA9CA12TSHR | |
| SCHEMBL6321590 | 0.84 | TDO2 (0.61) | CA2ALDH1A1CA9CA12TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | GONGWIN BIOPHARM CO., LTD (TW) | 2023-10-12 | — | — | US | disclosed |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| US-11752118-B2 | Method for treating melanoma | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| CN-115160123-A | Method for preparing carboxylic acid compound by oxidizing alcohol with oxygen as oxidant under catalysis of copper | 复旦大学 | 2022-10-11 | — | — | CN | disclosed |
| CN-113402477-B | Monofluoroolefin modified heteroatom cyclolactone or lactam derivative and synthetic method and application thereof | 华南理工大学 | 2022-06-14 | — | — | CN | disclosed |
| US-20220168248-A1 | METHOD FOR TREATING MELANOMA | GONGWIN BIOPHARM CO., LTD (TW) | 2022-06-02 | — | — | US | disclosed |
| CN-113402477-A | Monofluoroolefin modified heteroatom cyclolactone or lactam derivative and synthetic method and application thereof | 华南理工大学 | 2021-09-17 | — | — | CN | disclosed |
| US-20200338028-A1 | BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR MODULATING LIPID RAFT | GONGWIN BIOPHARM CO., LTD. (TW) | 2020-10-29 | — | — | US | disclosed |
| US-10548862-B2 | Topical formulation and method for preventing or treating acne | Wu, Lester J. (US) | 2020-02-04 | — | — | US | disclosed |
| WO-2019208721-A1 | HAIR MOISTURIZER, WHITENING AGENT, AND WHITENING COSMETIC | 株式会社成和化成 (JP) | 2019-10-31 | — | — | WO | disclosed |
| US-20130245011-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2013-09-19 | — | — | US | disclosed |
| US-8324207-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| US-7956052-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-07 | — | — | US | disclosed |
| US-20100087435-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-7659268-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-09 | — | — | US | disclosed |
| WO-2008145733-A2 | NOVEL CHEMICAL COMPOUNDS, PRODUCTION THEREOF, AND USE THEREOF | UNIVERSITÄT LEIPZIG (DE) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008145733-A2 | NOVEL CHEMICAL COMPOUNDS, PRODUCTION THEREOF, AND USE THEREOF | UNIVERSITÄT LEIPZIG (DE) | 2008-12-04 | — | — | WO | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087435-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CA2 2789/4885ALDH1A1 1786/4885CA9 4024/4885 |
| US-10548862-B2 | Topical formulation and method for preventing or treating acne | CUTA, STS, ALAD | CA2 4374/4885ALDH1A1 669/4885CA9 2493/4885 |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | LIPE, FABP4, LIPA | CA2 4175/4885ALDH1A1 728/4885CA9 1505/4885 |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | CA2 3603/4885ALDH1A1 3710/4885CA9 4302/4885 |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | CA2 226/4885ALDH1A1 1614/4885CA9 3637/4885 |
| US-20220168248-A1 | METHOD FOR TREATING MELANOMA | TYR, MITF, BRAF | CA2 1053/4885ALDH1A1 528/4885CA9 132/4885 |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | TP53, MCL1, TOP2B | CA2 989/4885ALDH1A1 381/4885CA9 76/4885 |
| US-11752118-B2 | Method for treating melanoma | TYR, MITF, BRAF | CA2 1053/4885ALDH1A1 528/4885CA9 132/4885 |
| US-20200338028-A1 | BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR MODULATING LIPID RAFT | ABCB4, SPTSSB, SMPD2 | CA2 4026/4885ALDH1A1 1604/4885CA9 3672/4885 |
| US-20130245011-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | CA2 2614/4885ALDH1A1 1991/4885CA9 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.